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Background: In the western world HCV is the leading etiologic factor of
HCC. Overall HCV impact on HCC-related mortality is increasing, but recent
data from Italy suggest an initial drop.
Aims: To evaluate epidemiology, clinical features and survival of HCV-related
HCC in a wide time range in Italy.
Methods: Multicenter retrospective study including 2769 patients prospec-
tively recruited by the ITA.LI.CA group. The patients were classified in
3 groups (Group A [G.A.], HCV associated or not with other etiologies,
Group B [G.B.], pure HCV, and Group C [G.C.], alternative etiologies) and
sub-grouped in 5 years time cohorts (1986-90, 91-95, 96-2000, 2001-2005)
but for the last one (2006-2008). Age, gender, Child-Pugh status, diagnosis
for surveillance, stage, thrombosis and metastases, treatment and survival
(Kaplan-Meier, Log-Rank) were analyzed.
Results: 1780 patients were included in G.A., 1430 in G.B., 989 in G.C. The
number of G.A. and G.B. patients reached a peak in the 1996-2000 to then
gradually drop, lowest values being observed in the last three years (p=0.0001
G.A., 0.01 G.B.). Mean age at diagnosis progressively increased in G.A.
(p<0.0001) and G.B. (p<0.001), but not in G.C, as did the percentage of cases
diagnosed under surveillance (G.A. p=0.019, G.B. p=0.0038) and the share
of patients in Child-Pugh A stage (G.A. p=0.01, G.B. p=0.007). Tumor size
decreased in all subgroups, stage improved significantly only in G.B. Median
survival significantly increased in all groups but more significantly in G.A.
and G.B., with a significant difference among G.A. and G.B. vs G.C. in the
last 3 time periods (p=0.02).
Conclusions: The incidence of HCC in HCV-related liver disease is decreas-
ing in Italy since 2001. HCV-related HCC patients are older, more frequently
diagnosed under surveillance, more frequently characterized by conserved
liver function and smaller tumors, with an earlier tumor stage when HCV
is the only etiologic factor. Finally their survival dramatically improved in
the last 15 years, more than in patients with different etiology. We therefore
expect a further drop in incidence and mortality for the disease in Italy in the
years to come.
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Background/Aims: SERPINB3 (S-B3), a serine protease inhibitor over-
expressed in hepatocellular carcinoma (HCC) and up-regulated by hypoxia
through a redox- and HIF2α-dependent mechanism, can stimulate EMT and
increased invasiveness in hepatic cancer cells. Along these lines, oncostatin
M (OSM) has been proposed to modulate hypoxia-dependent processes such
as liver development, regeneration and angiogenesis. Moreover, OSM-related
signaling pathway has been recently reported to operate by up-regulating
HIF1α. In the present we investigated whether OSM is expressed in human
HCC and whether it may be able to up-regulate S-B3 expression in human
hepatic cancer cells.
Methods: OSM and S-B3 expression has been investigated by immunohisto-
chemistry on liver specimens from HCV cirrhotic patients carrying G1 and G2
HCC. S-B3 expression has been investigated by employing morphological,
molecular and cell biology techniques in HepG2 and HuH7 cells exposed to
human recombinant OSM.
Results: In vivo analysis of OSM expression revealed that the cytokine was
expressed not only in cirrhotic tissue (as already shown by others) but also
in cancer cells of both G1 and G2 HCC. In particular, OSM-positive staining
in HCC was detected in some CD68 positive macrophages but mainly in
epithelial tumour cells of areas that were also positive for either HIF2α and
S-B3. Exposure of human hepatic cancer cells to recombinant OSM resulted
in a significant increase of S-B3 mRNA transcription within the first 24
hrs, followed by increased synthesis of the correspondent proteins at 48 hrs.
Similarly to what previously described for hypoxia-dependent up-regulation
of S-B3, OSM operated by inducing an early increase in intracellular reactive
oxygen species (ROS) and recruitment/stabilization of HIF2α.
Conclusions: OSM is overexpressed “in vivo” in human HCC cells in as-
sociation to HIF2α and S-B3. OSM and hypoxia, as independent signals,
can effectively up-regulate the expression of S-B3 in human cancer cells by
activating a common redox- and HIF2α-dependent mechanism.
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Background/Aims: Hepatic myofibroblasts (MFs) can originate from hepatic
stellate cells (HSC/MFs), portal fibroblasts or bone marrow-derived mes-
enchymal stem cells (MSCs) and can migrate towards the site of injury
and to align with nascent and established fibrotic septa in response to several
polypeptides, hypoxia or reactive oxygen species (ROS). Oncostatin M (OSM)
is known to orchestrate hypoxia-modulated hepatic processes (development,
regeneration, angiogenesis) involving HIF-1. Here we investigated signaling
mechanisms regulating migration of human HSC/MFs and human, MF-like
and bone marrow-derived, MSCs in response to oncostatin M.
Methods: Signal transduction was evaluated by integrating cell and molec-
ular biology techniques, whereas non-oriented migration and chemotaxis
were assessed by wound healing assay and the modified Boyden’s chambers
assay, respectively. Morphological analysis was performed by immunohisto-
chemistry (IHC) on liver specimens from HCV cirrhotic patients (Metavir
F4).
Results: IHC revealed positive stain for OSM in hepatocytes of cirrhotic
nodules, mainly in the proximity of fibrotic septa. Human recombinant OSM
stimulates non-oriented migration and chemotaxis in HSC/MFs and MSCs
involving the the following common features: (a) early intracellular ROS
generation and activation of Ras/Erk JNK1/2 as well as of STAT1 and STAT3
signaling pathways and involvement of hypoxia-inducible factor-1α (HIF-1α);
(b) OSM-dependent migration, which was inhibited by apocynin, indicating
NADPH-oxidase as a major source of ROS; (c) OSM-dependent motogenic
action that, similarly to hypoxia, appeared to be exerted in HSC/MFs and
MSCs through a biphasic mechanism requiring early generation of ROS and
late HIF1-dependent expression and release of VEGF.
Conclusions: OSM may contribute to fibrogenesis by stimulating directional
migration of human hepatic MFs through a biphasic, redox- and HIF-1α/
VEGF-dependent mechanism.
